There’s a ‘bearish-to-bullish’ reversal happening in this mid-cap biotech stock, says Carter Worth

view original post

In the throes of a “bearish-to-bullish” reversal, the stock exhibits bullish price-volume correlation and impressive relative strength to the market and to other biotechnology stocks. We’re buyers …